PARPi, BRCA, and gaps: controversies and future research

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Poly(ADP-ribose) polymerase inhibitors (PARPis) are approved cancer therapeutics targeting homologous recombination (HR) deficiency, often caused by BRCA1/2 mutations.
• Understanding the synthetic lethality induced by PARPis in HR-deficient cancers is crucial for optimizing treatment strategies.

Purpose of the Study:

• To review current debates and recent advancements in the application of PARPis for BRCA1/2-deficient cancers.
• To analyze the 'double-strand break (DSB)' and 'single-stranded DNA (ssDNA) gap' models of PARPi-induced synthetic lethality.
• To highlight the role of DNA polymerase theta (POLθ) and ssDNA gaps in therapeutic response and resistance.

Main Methods:

• Comprehensive literature review of ongoing debates and recent breakthroughs in PARPi therapy.
• Analysis of mechanistic models including DSB and ssDNA gap induction by PARPis.
• Scrutiny of emerging research on DNA polymerase theta (POLθ) and its impact on therapy.

Main Results:

• PARPi efficacy is complex, influenced by distinct synthetic lethality models and tumor heterogeneity.
• Emerging evidence implicates DNA polymerase theta (POLθ) and ssDNA gaps in modulating responses to PARPi.
• Mechanistic insights reveal potential drivers of PARPi resistance in BRCA-mutated cancers.

Conclusions:

• Bridging the gap between laboratory findings and clinical outcomes requires further research into PARPi mechanisms.
• Addressing tumor heterogeneity and resistance mechanisms is essential for improving PARPi efficacy in BRCA-mutated cancers.
• Further investigation into the roles of POLθ and ssDNA gaps may reveal novel therapeutic strategies.